BioCentury
ARTICLE | Clinical News

SYL040012: Phase II started

June 18, 2012 7:00 AM UTC

Sylentis said it began a placebo-controlled, dose-ranging, European Phase II trial to evaluate daily SYL040012 eye drops for 14 days in 80 patients. Sylentis is a subsidiary of Zeltia S.A. (Madrid:ZE...